Curocell, Inc.
🇰🇷South Korea
- Country
- 🇰🇷South Korea
- Ownership
- Public
- Established
- 2016-01-01
- Employees
- 102
- Market Cap
- -
- Website
- http://www.curocellbtx.com
Clinical Trials
1
Active:0
Completed:0
Trial Phases
1 Phases
Phase 1:1
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (1 trials with phase data)• Click on a phase to view related trials
Phase 1
1 (100.0%)Study of Efficacy and Safety of CRC01 in Adult Large B-cell Lymphoma Patients
Phase 1
Recruiting
- Conditions
- Relapsed Large B-cell LymphomaHigh-grade B-cell LymphomaRefractory Large B-cell LymphomaDiffuse Large B-cell Lymphoma (DLBCL)Primary Mediastinal Large B-Cell Lymphoma (PMBCL)Transformed Follicular Lymphoma (TFL)
- Interventions
- First Posted Date
- 2021-04-08
- Last Posted Date
- 2021-05-03
- Lead Sponsor
- Curocell Inc.
- Target Recruit Count
- 91
- Registration Number
- NCT04836507
- Locations
- 🇰🇷
Samsung Medical Center, Seoul, Korea, Republic of
News
No news found